^
    10ms
    An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer (clinicaltrials.gov)
    P2, N=115, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    gunagratinib (ICP-192)
    almost2years
    A Study of ICP-192 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Trial completion date: Feb 2023 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Nov 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    gunagratinib (ICP-192)
    almost2years
    A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=64, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P2 trial • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    gunagratinib (ICP-192)
    over3years
    Clinical Study of ICP-192 in Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Trial completion date: Jun 2021 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 fusion • FGFR2 translocation
    |
    gunagratinib (ICP-192)
    almost4years
    A Study of ICP-192 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Initiation date: Sep 2020 --> Feb 2021
    Clinical • Trial initiation date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    gunagratinib (ICP-192)
    4years
    A Study of ICP-192 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    Clinical • New P1/2 trial
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    gunagratinib (ICP-192)